| Type 2 Diabetes Mellitus |
1 |
1 |
| Biologic Therapy |
0 |
0.46 |
| Genomic Medicine |
0 |
0.44 |
| Europe |
0 |
0.43 |
| Precision Medicine |
0 |
0.43 |
| Chronic Kidney Disease |
0 |
0.4 |
| Renal Failure |
0 |
0.4 |
| COVID-19 |
0 |
0.35 |
| SGLT2 Inhibitor |
0 |
0.31 |
| Renal Disease |
0 |
0.3 |
| Hypoglycemia |
0 |
0.28 |
| Cardiovascular Imaging |
0 |
0.24 |
| Cardiovascular Risk Management |
0 |
0.24 |
| Heart Failure (HF) |
0 |
0.24 |
| Metabolic Syndrome |
0 |
0.22 |
| Endocrinology |
0 |
0.21 |
| Heart |
0 |
0.21 |
| Incretin Hormone |
0 |
0.21 |
| Kidney |
0 |
0.21 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.21 |
| Type 1 Diabetes Mellitus |
0 |
0.99 |
| GLP-1 Receptor Agonist |
0 |
0.19 |
| Biliary Disease |
0 |
0.18 |
| Non-Alcoholic Fatty Liver Disease |
0 |
0.18 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.17 |
| HIV Infection |
0 |
0.17 |
| Fatty Liver |
0 |
0.15 |
| Liver Disease |
0 |
0.15 |
| Obesity |
0 |
0.15 |
| Bone |
0 |
0.14 |
| Ejection Fraction |
0 |
0.14 |
| Electronic Health Record (EHR) and Healthcare Technology |
0 |
0.14 |
| Hospital |
0 |
0.14 |
| Liver |
0 |
0.14 |
| Neuropathy |
0 |
0.14 |
| Pandemic |
0 |
0.95 |
| Receptors |
0 |
0.14 |
| Patient Safety |
0 |
0.11 |
| Hemoglobin A1c |
0 |
0.1 |
| Wound Healing |
0 |
0.1 |
| Wound Management |
0 |
0.1 |
| Abdomen |
0 |
0.07 |
| Adverse Effects |
0 |
0.07 |
| Artificial Intelligence |
0 |
0.07 |
| Autoimmune Disease |
0 |
0.07 |
| Clinical Guidelines |
0 |
0.07 |
| Clinical Research |
0 |
0.07 |
| Comparative Effectiveness |
0 |
0.07 |
| COVID-19 and Diabetes |
0 |
0.97 |
| Diabetes Research |
0 |
0.98 |
| Diabetic Ketoacidosis |
0 |
0.07 |
| Geriatrics |
0 |
0.07 |
| Hemoglobin |
0 |
0.07 |
| Hyperglycemia |
0 |
0.07 |
| Metabolism |
0 |
0.07 |
| Orbit |
0 |
0.07 |
| Psychosocial |
0 |
0.07 |
| Severe Acute Respiratory Syndrome |
0 |
0.07 |
| Tissue |
0 |
0.07 |
| Weight Loss |
0 |
0.07 |
| Wound |
0 |
0.07 |
| Acute Respiratory Distress Syndrome |
0 |
0.06 |
| Weight Management |
0 |
0.06 |